Myocardial Infarction
0.300
Biomarker
disease
CTD_human
Long-term oral resveratrol intake provides nutritional preconditioning against myocardial ischemia/reperfusion injury: involvement of VDAC1 downregulation.
25488258 2015
Myocardial Reperfusion Injury
0.300
Biomarker
phenotype
CTD_human
Long-term oral resveratrol intake provides nutritional preconditioning against myocardial ischemia/reperfusion injury: involvement of VDAC1 downregulation.
25488258 2015
Ventricular Dysfunction, Left
0.300
Biomarker
phenotype
CTD_human
Long-term oral resveratrol intake provides nutritional preconditioning against myocardial ischemia/reperfusion injury: involvement of VDAC1 downregulation.
25488258 2015
Diabetic Nephropathy
0.300
Biomarker
disease
CTD_human
Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats.
19634143 2009
Nodular glomerulosclerosis
0.300
Biomarker
disease
CTD_human
Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats.
19634143 2009
Epilepsy
0.300
Biomarker
disease
CTD_human
Preliminary explorations of the role of mitochondrial proteins in refractory epilepsy: some findings from comparative proteomics.
17893921 2007
Epilepsy, Cryptogenic
0.300
Biomarker
disease
CTD_human
Preliminary explorations of the role of mitochondrial proteins in refractory epilepsy: some findings from comparative proteomics.
17893921 2007
×
CUI: C0236018
Disease:
Aura
Aura
0.300
Biomarker
phenotype
CTD_human
Preliminary explorations of the role of mitochondrial proteins in refractory epilepsy: some findings from comparative proteomics.
17893921 2007
Awakening Epilepsy
0.300
Biomarker
disease
CTD_human
Preliminary explorations of the role of mitochondrial proteins in refractory epilepsy: some findings from comparative proteomics.
17893921 2007
Psychomotor Disorders
0.300
Biomarker
group
CTD_human
Deficiency of the voltage-dependent anion channel: a novel cause of mitochondriopathy.
8726225 1996
Megaconial Myopathies
0.300
Biomarker
disease
CTD_human
Deficiency of the voltage-dependent anion channel: a novel cause of mitochondriopathy.
8726225 1996
Pleoconial Myopathies
0.300
Biomarker
disease
CTD_human
Deficiency of the voltage-dependent anion channel: a novel cause of mitochondriopathy.
8726225 1996
Mitochondrial Myopathies
0.300
Biomarker
group
CTD_human
Deficiency of the voltage-dependent anion channel: a novel cause of mitochondriopathy.
8726225 1996
Motor retardation
0.300
Biomarker
phenotype
CTD_human
Deficiency of the voltage-dependent anion channel: a novel cause of mitochondriopathy.
8726225 1996
Developmental Psychomotor Disorders
0.300
Biomarker
group
CTD_human
Deficiency of the voltage-dependent anion channel: a novel cause of mitochondriopathy.
8726225 1996
Luft Disease
0.300
Biomarker
disease
CTD_human
Deficiency of the voltage-dependent anion channel: a novel cause of mitochondriopathy.
8726225 1996
Diabetes Mellitus, Experimental
0.200
Biomarker
disease
RGD
Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats.
19634143 2009
Visual seizure
0.200
Therapeutic
disease
RGD
Preliminary explorations of the role of mitochondrial proteins in refractory epilepsy: some findings from comparative proteomics.
17893921 2007
Malignant Neoplasms
0.100
Biomarker
group
BEFREE
These data identify the MFF-VDAC1 complex as a novel regulator of mitochondrial cell death and an actionable therapeutic target in cancer .
31582380 2019
Malignant Neoplasms
0.100
Biomarker
group
BEFREE
The results thus show that VDAC1 depletion-mediated cancer cell metabolic reprograming involves a chain of events occurring in a sequential manner leading to a reversal of the unique properties of the tumor, indicative of the interplay between metabolism and oncogenic signaling networks.
31661894 2019
Malignant Neoplasms
0.100
AlteredExpression
group
BEFREE
VDAC1 is one of the most studied members of the VDAC protein family and is overexpressed in multiple types of cancer .31452730 2019
Malignant Neoplasms
0.100
Biomarker
group
BEFREE
An MFF-VDAC1 complex is a novel regulator of mitochondrial integrity and actionable therapeutic target in cancer .
31542392 2019
Malignant Neoplasms
0.100
Biomarker
group
BEFREE
As depletion of CCP2 or inhibition of VDAC1 reverses the effects of RARRES1 depletion on energy balance and cell survival we conclude that RARRES1 modulation of CCP2-modulated tubulin-mitochondrial VDAC1 interactions is a fundamental regulator of cancer and stem cell metabolism and survival.
30899431 2019
Malignant Neoplasms
0.100
Biomarker
group
BEFREE
Although VDAC1 silencing occurred within a day, the cells underwent reprograming with respect to rewiring metabolism, elimination of cancer stem cells (CSCs), and alteration of transcription factor (TF) expression and proteins associated with differentiation, with maximal changes being observed after 3 weeks of silencing VDAC1 expression.
31195298 2019
Neoplasms
0.100
AlteredExpression
group
BEFREE
SIGNIFICANCE: These findings describe mitochondrial fission regulation using a peptidomimetic agent that disturbs the MFF-VDAC complex and displays anticancer activity in multiple tumor models.<i>See related commentary by Rao, p. 6074</i>.
31582380 2019